Roivant Sciences Company Insiders
ROIV Stock | USD 12.71 0.02 0.16% |
Roivant Sciences' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Roivant Sciences suggests that vertually all insiders are panicking. Roivant Sciences employs about 908 people. The company is managed by 19 executives with a total tenure of roughly 2119 years, averaging almost 111.0 years of service per executive, having 47.79 employees per reported executive.
Roivant Sciences' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-20 | Eric Venker | Disposed 100000 @ 11.32 | View | ||
2024-10-21 | Eric Venker | Disposed 100000 @ 11.65 | View | ||
2024-09-26 | Financial Lp Qvt | Disposed 876000 @ 11.82 | View | ||
2024-09-24 | Keith S Manchester | Disposed 368052 @ 11.62 | View | ||
2024-09-23 | Rakhi Kumar | Disposed 250000 @ 11.89 | View | ||
2024-02-09 | Eric Venker | Disposed 96950 @ 10.92 | View | ||
2024-01-02 | Vivek Ramaswamy | Disposed 3000000 @ 11.05 | View |
Monitoring Roivant Sciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Roivant |
Roivant Sciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.1844) % which means that it has lost $0.1844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.2896 %, meaning that it created $1.2896 on every $100 dollars invested by stockholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to 0.64 in 2024. Return On Capital Employed is likely to climb to 0.64 in 2024. At this time, Roivant Sciences' Asset Turnover is fairly stable compared to the past year.Common Stock Shares Outstanding is likely to drop to about 610.3 M in 2024. Net Loss is likely to climb to about (862.7 M) in 2024
Roivant Sciences Workforce Comparison
Roivant Sciences is rated second in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 15,905. Roivant Sciences holds roughly 908 in number of employees claiming about 6% of equities under Health Care industry.
Roivant Sciences Profit Margins
The company has Profit Margin (PM) of 37.25 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of (74.46) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $74.46.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.95 | 0.7759 |
|
|
Roivant Sciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Roivant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Roivant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Roivant Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.4545 | 5 | 11 | 205,147 | 448,035 |
2024-09-01 | 0.6765 | 23 | 34 | 38,725,865 | 10,481,120 |
2024-06-01 | 0.2917 | 7 | 24 | 577,845 | 41,242,883 |
2024-03-01 | 0.2 | 7 | 35 | 1,224,081 | 128,615,479 |
2023-12-01 | 0.3448 | 10 | 29 | 1,589,822 | 3,838,106 |
2023-09-01 | 0.5217 | 48 | 92 | 2,374,705 | 41,871,998 |
2023-06-01 | 0.4615 | 30 | 65 | 3,012,554 | 46,285,932 |
2023-03-01 | 0.1333 | 2 | 15 | 4,457 | 16,216,673 |
2022-12-01 | 0.129 | 4 | 31 | 4,007,794 | 24,196,828 |
2022-09-01 | 1.5556 | 14 | 9 | 995,843 | 117,414 |
2022-06-01 | 1.4444 | 13 | 9 | 103,211,074 | 340,550 |
2021-12-01 | 0.0189 | 1 | 53 | 313,419 | 85,897,655 |
Roivant Sciences Notable Stakeholders
A Roivant Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Roivant Sciences often face trade-offs trying to please all of them. Roivant Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Roivant Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
PharmD MD | President COO | Profile | |
Mayukh MD | Chief President | Profile | |
Amy Mahery | Chief Officer | Profile | |
Matthew Gline | CEO Director | Profile | |
Marianne Romeo | Head Management | Profile | |
Huafeng Xu | Chief Officer | Profile | |
Josh Chen | General Counsel | Profile | |
Matt Maisak | Chief Platforms | Profile | |
Vivek Ramaswamy | Founder Chairman | Profile | |
Alex Gasner | Executive Health | Profile | |
Jo Chen | General Counsel | Profile | |
Drew Kramer | Chief Officer | Profile | |
Kelly Graff | Head People | Profile | |
Richard Pulik | Chief Officer | Profile | |
Deya MD | Chief OfficerInResidence | Profile | |
Srini Ramanathan | Chief Officer | Profile | |
Rakhi Kumar | Chief Officer | Profile | |
Josh JD | General Counsel | Profile | |
David MD | Chief Dermavant | Profile |
About Roivant Sciences Management Performance
The success or failure of an entity such as Roivant Sciences often depends on how effective the management is. Roivant Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Roivant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Roivant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.61 | 0.64 | |
Return On Capital Employed | 0.61 | 0.64 | |
Return On Assets | 0.60 | 0.63 | |
Return On Equity | 0.73 | 0.77 |
Please note, the imprecision that can be found in Roivant Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Roivant Sciences. Check Roivant Sciences' Beneish M Score to see the likelihood of Roivant Sciences' management manipulating its earnings.
Roivant Sciences Workforce Analysis
Traditionally, organizations such as Roivant Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Roivant Sciences within its industry.Roivant Sciences Manpower Efficiency
Return on Roivant Sciences Manpower
Revenue Per Employee | 137.4K | |
Revenue Per Executive | 6.6M | |
Net Income Per Employee | 4.7M | |
Net Income Per Executive | 222.7M | |
Working Capital Per Employee | 7.1M | |
Working Capital Per Executive | 340.3M |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.